spacer
home > ebr > summer 2002 > contract development - industry spend and value
PUBLICATIONS
European Biopharmaceutical Review

Contract Development - Industry Spend and Value

We have entered a period of growth in the drug development industry, driven largely by financial investment and an increase in validated targets. This expansion has created a competitive need for finite drug development resources. As an employee of a preclinical testing company, I will be drawing on my experiences to comment on the value of the contract research organisation (CRO) and the growth of contract research, explaining these in the context of the biopharmaceutical industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Benjamin Jones, Business Development Manager at Huntingdon Life Sciences Ltd
Dr Benjamin Jones has a bachelor's degree in Zoology from Nottingham University, and received his PhD from the Welsh School of Pharmacy at Cardiff University.
After a short academic career he joined Huntingdon Life Sciences (HLS) Business Development Group in early 2000. Ben has worked for Huntingdon in the US and the UK and is currently responsible for biopharmaceutical and inhalation toxicology business development.

spacer
Dr Benjamin Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement